Stockreport

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

PharmaCyte Biotech, Inc.  (PMCB) 
NASDAQ:AMEX Investor Relations: ir.pharmacytebiotech.com
PDF Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value LAS V [Read more]